Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

October 24, 2023

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

News Conference News TCT 2020

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

October 18, 2020

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

September 28, 2019

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

News Conference News TCT 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

September 24, 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

September 22, 2018

News Conference News TCT 2016

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

November 07, 2016

Evaluation of Long-term Vascular Responses to Fluorocopolymer coated Self-Expanding low-dose Paclitaxel-eluting Stent in Porcine Ilio-femoral Model

Presentation TCT 2013

Evaluation of Long-term Vascular Responses to Fluorocopolymer coated Self-Expanding low-dose Paclitaxel-eluting Stent in Porcine Ilio-femoral Model

Presenter: Dongming Hou, Barbara Huibregtse, William Stoffregen, Gordon Kocur, Cory Hitzman, Elizabeth Stejskal, John Heil, Keith Dawkins

January 31, 2013

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.